Discovery and optimization of novel purines as potent and selective CB2 agonists.

Hollinshead, Sean P; Astles, Peter C; Chambers, Mark G; Johnson, Michael P; Palmer, John; Tidwell, Michael W

Hollinshead, Sean P; Astles, Peter C; Chambers, Mark G; Johnson, Michael P; Palmer, John; Tidwell, Michael W.

Affiliation

Hollinshead SP; Discovery Chemistry, Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. hollinshead_sean_p@lilly.com

Bioorg Med Chem Lett ; 22(15): 4962-6, 2012 Aug 01.

Article in En | MEDLINE | ID: mdl-22765893

Subject(s)

Furans/chemistry; Purines/chemistry; Receptor, Cannabinoid, CB2/agonists; Animals; Drug Evaluation, Preclinical; Furans/pharmacokinetics; Furans/therapeutic use; Half-Life; Humans; Pain/drug therapy; Purines/pharmacokinetics; Purines/therapeutic use; Rats; Receptor, Cannabinoid, CB1/agonists; Receptor, Cannabinoid, CB1/metabolism; Receptor, Cannabinoid, CB2/metabolism; Structure-Activity Relationship

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purines / Receptor, Cannabinoid, CB2 / Furans Limits: Animals / Humans Language: En Journal: Bioorg Med Chem Lett Journal subject: BIOQUIMICA / QUIMICA Year: 2012 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google